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Accepted 25 January 2016; Published online 2 February 2016AbstractObjectives: Search for biomarkers for early detection of cancer is a very active area of research, but most studies are done in clinical rather
than screening settings. We aimed to empirically evaluate the role of study setting for early detection marker identification and validation.
Study Design and Setting: A panel of 92 candidate cancer protein markers was measured in 35 clinically identified colorectal cancer
patients and 35 colorectal cancer patients identified at screening colonoscopy. For each case group, we selected 38 controls without colo-
rectal neoplasms at screening colonoscopy. Single-, two- and three-marker combinations discriminating cases and controls were identified
in each setting and subsequently validated in the alternative setting.
Results: In all scenarios, a higher number of predictive biomarkers were initially detected in the clinical setting, but a substantially
lower proportion of identified biomarkers could subsequently be confirmed in the screening setting. Confirmation rates were 50.0%,
84.5%, and 74.2% for one-, two-, and three-marker algorithms identified in the screening setting and were 42.9%, 18.6%, and 25.7%
for algorithms identified in the clinical setting.
Conclusion: Validation of early detection markers of cancer in a true screening setting is important to limit the number of false-positive
findings.  2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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For most cancers, prognosis strongly varies by stage at
diagnosis, and the prospect of cure is much higher when
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licenses/by-nc-nd/4.0/).validation of biomarkers for early detection of cancer is
therefore a very active area of research [1e3]. Ideally,
pertinent studies should be conducted in a true screening
setting to provide reliable estimates of diagnostic perfor-
mance in the target population for screening [4e6]. Howev-
er, this is rarely done in practice for several reasons: First,
the prevalence of preclinical cancer overall and of specific
cancers in particular in the target population for cancer
screening (which typically consists of essentially healthy
older adults) is typically very low [7]. Therefore, very large
study populations are required to ensure sufficient numbers
of cases to estimate sensitivity and other indicators of diag-
nostic performance with adequate precision. Second, there
is often no easy to perform and reliable gold standardess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 Most studies searching for novel biomarkers for
early detection of cancer are conducted in clinical
settings, that is, using clinically detected cases.
Biomarker levels among such cases may differ
from biomarker levels among preclinical cases to
be detected by screening for a variety of reasons.
Biomarkers identified in such studies may there-
fore be of questionable use unless they are vali-
dated in a true screening setting.
 The authors provide a thorough quantitative illustra-
tion of the importance of validation of biomarkers
for early detection of cancer in a true screening
setting using the example of blood protein markers
for early detection of colorectal cancer.
What is the implication and what should change
now?
 The interpretation of caseecontrol studies based
on patients from clinical settings requires partic-
ular caution, due to the potential high proportion
of false-positive findings.
 Validation of early detection biomarkers of cancer
in a true screening setting is important to limit the
number of false-positive findings.
examination (such as colonoscopy for colorectal cancer
detection) to which measurements of biomarkers could be
compared and that could be applied in such large screening
populations.
In practice, it is commonly seen that studies evaluating
biomarkers for early detection of cancer therefore recruit
a sample of cancer cases in a clinical setting (e.g., newly
diagnosed cancer patients admitted to a single or multiple
clinics), along with a sample of controls without a known
cancer diagnosis [8,9]. Moreover, controls often consist
of convenience samples, such as patients from different
clinic departments or healthy volunteers, and they often
strongly differed from the case groups in many respects,
including basic sociodemographic factors [10], such as
presence of other diseases or age, which may have impor-
tant implications for specificity. Under such circumstances,
any differences in biomarker levels between cancer patients
and controls need to be interpreted with caution because
they could simply reflect such differences rather than
cancer-related differences. In some studies, matching by
key sociodemographic factors, such as sex and age, is used
to reduce the risk of such bias, but such matching does not
eliminate other sources of differences, such as preceding
diagnostic measures that led to the diagnosis of cases or
H. Chen et al. / Journal of Clinieven early treatment. Furthermore, even seemingly perfect
matching by factors such as sex and age may sometimes
introduce or increase rather than eliminate bias because
in a true screening setting, age and sex distribution of those
with and without cancer is often not identical [11]. Finally,
clinically manifest cases are by definition different from
preclinical cancers searched for in a screening setting,
and they may differ with respect to a number of factors that
favor clinical diagnosis, such as cancer size or stage [10].
It is therefore not surprising that very promising results
for the diagnostic performance of cancer early detection
markers initially obtained in studies conducted in clinical
settings could often not be confirmed in later validations
in screening settings. On the other hand, it could be antic-
ipated that good diagnostic performance in screening
settings should more often go along with good diagnostic
performance in clinical settings. This is because studies
conducted in screening populations should primarily iden-
tify cancer-related differences (e.g., different expression
patterns of tumor-associated biomarkers) between cases
and controls which would also be expected to apply to
clinical settings. However, evidence on differences in
confirmation rates of early detection markers identified in
clinical and screening settings from systematic comparative
assessment is still sparse. In this study, we provide such an
assessment, using the search for blood protein biomarkers
for early detection of colorectal cancer as an example.2. Methods
2.1. Study design
We compared the frequency of initial identification and
subsequent validation of protein markers and protein
marker combinations indicative of presence of colorectal
cancer for the following two scenarios:
1) Use of clinically detected cases in the marker identi-
fication set and cases detected in a true screening
setting in the validation set.
2) Use of cases detected in a true screening setting in the
marker identification set and clinically detected cases
in the validation set.
In both scenarios, two sets of participants confirmed to
be free of colorectal neoplasms at screening colonoscopy
were used as controls.
For this comparison, number and composition of study
participants in the clinical setting and the screening setting
were kept identical. To achieve statistically robust results, a
large number of biomarkers and their combinations were
evaluated: 92 single protein markers,

92
2

54; 186 two-
marker combinations, and

92
3

5125; 580 three-marker
combinations.
110 H. Chen et al. / Journal of Clinical Epidemiology 75 (2016) 108e1142.2. Study populations
Subjects from the screening setting were recruited in the
context of the BliTz study, which is an ongoing study
among participants of screening colonoscopy conducted
in cooperation with 20 gastroenterology practices in
South-western Germany since November 2005. Detailed in-
formation on the BliTz study has been reported elsewhere
[12,13]. Briefly, the aim of this study was to evaluate novel
tests for early detection of colorectal cancer (CRC). Partic-
ipants were invited to provide blood and stool samples
before the screening colonoscopy. The following exclusion
criteria were applied in this analysis to ensure the condition
of a true screening setting and to minimize the risk of false-
negative results at screening colonoscopy: blood samples
taken after screening colonoscopy or blood samples with
unknown date of blood withdrawal, history of CRC or in-
flammatory bowel disease, previous colonoscopy in the last
5 years or unknown colonoscopy history, incomplete colo-
noscopy, or insufficient bowel preparation (latter two
criteria only for controls). From the remaining participants
of the BliTz study recruited in 20052012 (N 5 4,345), all
35 available cases with newly detected CRC were included
in the analysis. For comparison, we included a representa-
tive sample of 38 controls free of colorectal neoplasms.
As cases representing the clinical setting, we included
35 clinically detected CRC cases recruited at four hospitals
in Southern Germany. Blood samples were withdrawn
before any treatment from each participant. Another 38
randomly selected controls free of colorectal neoplasms
from the BliTz study were included for comparison. Iden-
tical standard operation procedures were used for handling
of blood samples in both settings. Plasma samples were
centrifuged at 2,123g for 10 minutes at 4C and stored at
80C until analyses.
Written informed consent was obtained from each
participant. All studies were approved by the ethics
committees of the medical faculty of the University of Hei-
delberg and of the respective state medical boards.2.3. Blood protein biomarkers
Ninety-two predefined human tumor-associated protein
biomarkers were measured in 146 samples using Proseek
Multiplex Oncology I9696 (Olink Bioscience, Uppsala,
Sweden) (full marker list is provided in Supplementary
Table S1 at www.jclinepi.com). All laboratory operations
were conducted according to the Proseek Multiplex
Oncology I9696 User Manual in the TATAA Biocenter
(G€oteborg, Sweden) [14]. In short, the Proseek reagents
are based on the Proximity Extension Assay technology
[15], where 92 oligonucleotide labeled antibody probe pairs
are allowed to bind to their respective target present in the
sample. A polymerase chain reaction (PCR) reporter
sequence is formed by a proximity dependent DNA poly-
merization event and is subsequently detected andquantified using real-time PCR. All information regarding
the study population was blind to the laboratory operators.
Two independent analyses were conducted: 35 CRC sam-
ples recruited in the clinical setting and 38 controls were
measured in a first analysis, and the 35 CRC samples and
38 controls recruited in the screening setting were
measured in a second analysis.2.4. Statistical analysis
Age, sex, and tumor stage distribution (CRC cases only)
are reported by descriptive statistics. As identification of
biomarkers showing different distributions of biomarker
values is typically the first step in the early phase of
biomarker research for cancer early detection, we used Wil-
coxon rank sum test to identify single biomarkers showing
statistically significant differences in plasma levels of CRC
cases and controls. Additionally, receiver operating charac-
teristics (ROC) analysis was conducted, and the areas under
the ROC curves are reported. Two- and three-marker com-
binations were evaluated by multiple logistic regression
models, and likelihood ratio tests comparing the full model
(including the two markers or three markers and intercept)
and the null model (including the intercept only) were used
to test for statistical significance. Apart from unadjusted
P-values, P-values adjusted for multiple testing using the
BenjaminieHochberg method are also reported [16].
Furthermore, to eliminate potential confounding by age
and sex, results from age and sex adjusted logistic regres-
sion models are also reported.
All statistical analyses were performed with the statistical
softwareR version 3.1.1 [17]. All tests were two sided, andP-
values less than 0.05 or false discovery rates (FDRs) less than
5% were considered to indicate statistical significance.3. Results
Table 1 presents main characteristics of colorectal can-
cer cases recruited in the clinical setting and the screening
setting and their controls. Sex, age, and stage distribution
were roughly comparable between both samples. There
were more men than women in both CRC patient groups.
The control groups included more women, and the propor-
tions in the both control groups were the same (57.9%).
Patients with CRC were slightly older than controls in both
study samples. The differential sex and age distributions of
cases and controls reflect the sex distributions encountered
in colonoscopy screening in Germany [10].
Table 2 shows the results of single biomarkers that were
found to show statistically significant differences in the
clinical setting, with replication in the screening setting.
Overall, 25 biomarkers were identified to show statistically
significant differences of plasma levels between CRC cases
recruited in the clinical setting and controls, but only six of
them (6/25 5 24%) were confirmed in the screening
Table 1. Characteristics of colorectal cancer cases recruited in the clinical setting and the screening setting and their controls
Sample characteristics
Clinical setting Screening setting
Colorectal cancer Controls Colorectal cancer Controls
N 35 38 35 38
Men [N (%)] 22 [62.9] 16 [42.1] 25 [71.4] 16 [42.1]
Age [mean (SD) years] 68.0 [8.5] 60.7 [6.0] 66.9 [6.5] 62.7 [7.1]
TNM tumor stage [N (%)]
Early stage (stage I/II) 19 [54.3] e 17 [48.5] e
Advanced stage (stage III/IV) 16 [45.7] e 18 [51.4] e
Abbreviation: SD, standard deviation; TNM, tumor-node-metastasis.
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ple testing, of seven single biomarkers still showing statis-
tically significant results in the clinical setting, only 3
biomarkers (3/7 5 43%) were successfully replicated in
the screening setting samples.
Table 3 lists the results of single biomarkers that were
found to show statistically significant differences in the
screening setting, with replication in the clinical setting.
Overall, of 15 single markers showing statistically signifi-
cant results in the screening setting, six biomarkers
(6/15 5 40%) were successfully replicated in the clinical
setting. When using 5% FDR as the cutoff level for multi-
ple testing, of four biomarkers showing statistically signif-
icant results, two biomarkers (50%) were confirmed in the
clinical setting.Table 2. Protein markers with significant differences in clinical setting (P !
Marker
Identification in the clinical setting
AUC Unadjusted P-value Adjusted P-v
Adrenomedullin 0.81 !0.001 !0.001
Amphiregulin 0.81 !0.001 !0.001
GDF-15 0.81 !0.001 !0.001
Cathepsin-D 0.75 !0.001 0.005
PlGF 0.74 !0.001 0.005
EGFR 0.73 !0.001 0.007
IL-6 0.71 0.002 0.027
HGF 0.69 0.005 0.056
Follistatin 0.68 0.008 0.076
TNF-RI 0.68 0.008 0.076
Osteoprotegerin 0.68 0.009 0.076
ErbB3-Her3 0.66 0.016 0.110
HE4 0.66 0.016 0.110
CSF-1 0.66 0.017 0.110
MIC-A 0.66 0.019 0.116
PSA 0.65 0.020 0.116
VEGF-A 0.65 0.023 0.123
VEGFR-2 0.65 0.024 0.123
TNF-R2 0.65 0.028 0.135
CXCL13 0.65 0.030 0.139
Flt3L 0.65 0.032 0.140
CXCL11 0.64 0.038 0.158
Midkine 0.64 0.042 0.162
Prostasin 0.64 0.042 0.162
REG-4 0.64 0.045 0.164
Abbreviation: AUC, area under the receiver operating characteristic curv
Bold indicates statistically significant.
a The P-value was adjusted for multiple testing using BenjaminieHochb
!5%.Detailed comparisons of results on two- and three-
marker combinations are shown in Table 4. These compar-
isons confirm, for the much larger numbers of marker com-
binations, the above described pattern: higher number of
initially identified markers but lower subsequent confirma-
tion proportions when identification is done in the clinical
setting compared to marker identification in the screening
setting. The confirmation rates (results after adjustment
for multiple testing) for two- and three-marker combina-
tions identified in the clinical setting were 18.6% (221/
1,188) and 25.7% (12,927/50,291), respectively. In the
screening setting, smaller numbers of significant marker
combinations were initially identified, but much higher
confirmation rates were achieved. The confirmation rates
were 84.5% (239/283) and 74.2% (11,653/15,703) for0.05) and their replication in the screening setting
Replication in the screening setting
aluea AUC Unadjusted P-value Adjusted P-valuea
0.61 0.099 0.118
0.74 !0.001 0.002
0.72 0.001 0.004
0.62 0.073 0.118
0.61 0.101 0.118
0.59 0.196 0.196
0.70 0.004 0.009
0.53 0.665 d
0.60 0.160 d
0.56 0.376 d
0.56 0.382 d
0.59 0.192 d
0.58 0.220 d
0.50 1.000 d
0.51 0.925 d
0.67 0.013 d
0.51 0.926 d
0.64 0.043 d
0.65 0.032 d
0.59 0.167 d
0.59 0.203 d
0.60 0.138 d
0.55 0.479 d
0.56 0.382 d
0.55 0.432 d
e.
erg method. Statistical significance was defined as false discovery rate
Table 3. Protein markers with significant differences in screening setting (P ! 0.05) and their replication in the clinical setting
Marker
Identification in the screening setting Replication in the clinical setting
AUC Unadjusted P-value Adjusted P-valuea AUC Unadjusted P-value Adjusted P-valuea
Amphiregulin 0.74 !0.001 0.021 0.81 !0.001 !0.001
CXCL9 0.73 0.001 0.021 0.62 0.082 0.054
CEA 0.73 0.001 0.021 0.63 0.051 0.068
GDF-15 0.72 0.001 0.028 0.81 !0.001 !0.001
IL-6 0.70 0.004 0.062 0.71 0.002 d
CXCL10 0.69 0.004 0.062 0.57 0.314 d
PSA 0.67 0.013 0.161 0.65 0.020 d
IFN-gamma 0.67 0.014 0.161 0.56 0.413 d
ErbB4-Her4 0.66 0.017 0.171 0.56 0.359 d
TNFRSF4 0.65 0.031 0.254 0.60 0.163 d
TNF-R2 0.65 0.032 0.254 0.65 0.028 d
CA-125 0.64 0.033 0.254 0.61 0.098 d
VEGFR-2 0.64 0.043 0.285 0.65 0.024 d
E-selectin 0.64 0.043 0.285 0.50 0.987 d
TNF-alpha 0.63 0.048 0.295 0.58 0.213 d
Abbreviation: AUC, area under the receiver operating characteristic curve.
Bold indicates statistically significant.
a The P-value was adjusted for multiple testing using the BenjaminieHochberg method. Statistical significance was defined as false discovery
rate !5%.
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adjusting for age and sex, numbers of identified and
confirmed markers and marker combinations were reduced.
Nevertheless, higher confirmation rates were still observed
for marker combinations derived from the screening setting
than for those derived from the clinical setting.4. Discussion
Our empirical example demonstrates that using samples
from the clinical setting for identification of cancer early
detection biomarkers might result in a large amount of
false-positive findings which cannot be reproduced in a true
screening setting. In our example, the confirmation rates
(results adjusting for multiple testing) of single-, two-,
and three-marker combinations identified initially in the
clinical setting were only 42.9%, 18.6% and 25.7%, respec-
tively, if subsequently validated in the screening setting.
These confirmation rates were much lower than the confir-
mation rates of markers and marker combinations identified
in a true screening setting. Our results underline theTable 4. The comparison of significant single biomarkers, two-, and three-m
Approaches (training set/ validation set) Adjustment
Single
(N [
Number
Clinical setting/ screening setting No 25/ 6
Screening setting/ clinical setting No 15/ 6
Clinical setting/ screening setting Multiple testingb 7/ 3
Screening setting/ clinical setting Multiple testingb 4/ 2
Clinical setting/ screening setting Age and sex 10/ 2
Screening setting/ clinical setting Age and sex 7/ 2
a Percentage of markers that could be replicated in the validation settin
b The P-value was adjusted for multiple testing using the BenjaminieHo
rate !5%.necessity of validating promising biomarker findings in
prospective samples from screening settings to limit the
number of false-positive findings.
Biomarker research on early detection of cancer is blos-
soming. However, most present studies are still in the early
phase aiming for marker discovery [18]. Strong claims of
novel biomarkers for early diagnosis are commonly re-
ported, but often show weak or no reproducibility
[19,20]. Part of this phenomenon might be due to the
widely used caseecontrol study design in the biomarker
discovery phase [8,21]. In such a study design, cancer cases
are typically symptomatic patients recruited from hospitals
and corresponding controls are often convenience samples,
such as patients with different diseases recruited from the
same hospital, blood donors, or other healthy volunteers.
There are numerous reasons why apparently most prom-
ising biomarkers identified in such settings may often not
be confirmed in subsequent validation in true screening set-
tings. First, clinically confirmed diagnoses of cancer re-
cruited in clinical settings may differ from preclinical
cases searched for in screening settings with respect to aarker combinations between the two settings
marker
92)
Two-marker combination
(N [ 4,186)
Three-marker combination
(N [ 125,580)
%a Number %a Number %a
24.0 1,834/ 633 34.5 66,332/ 26,507 40.0
40.0 957/ 633 66.1 38,392/ 26,507 69.0
42.9 1,188/ 221 18.6 50,291/ 12,927 25.7
50.0 283/ 239 84.5 15,703/ 11,653 74.2
20.0 881/ 179 20.3 33,054/ 7,927 24.0
28.6 584/ 179 30.7 21,481/ 7,927 36.9
g.
chberg method. Statistical significance was defined as false discovery
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graphic factors (e.g., age, sex), tumor characteristics (e.g.,
stage at diagnosis, location, grade, and so forth), and clin-
ical factors (e.g., diagnosis and treatment-related factors).
Second, convenience samples may likewise often substan-
tially differ from controls recruited in a true screening
setting with respect to sociodemographic factors or factors
related to their specific diseases (when controls with
another disease are used). Third, sample handling and pre-
analytical sample processing may often substantially differ
between samples collected in clinical and screening settings
[22,23]. Fourth, apparent diagnostic performance of bio-
markers identified in a specific data set may generally be
overoptimistic and often not be replicated unless adequate
measures are taken [24], such as correction for multiple
testing (especially for studies testing a large number of bio-
markers simultaneously in a limited number of samples)
[25,26], internal validation (i.e., bootstrap and cross-
validation) [27], or external validation in an independent
data set [27,28].
In our analyses, we already minimized the potential for
bias by most of these sources. In particular, we used iden-
tical standard operation procedures for obtaining and
processing blood samples in both the clinical and the
screening setting. Moreover, we used comparable control
groups from a true screening setting for both groups of
cases. Although these control groups differed from the case
groups with respect to age and sex distribution to some
extent, this difference reflects the true difference between
cases and controls to be expected in a true screening setting
and does not introduce bias when judging the performance
of early detection markers in such a setting [11]. Despite
minimizing the aforementioned sources of bias, initial
discovery of biomarkers using cases recruited in the clinical
setting still led to substantially larger numbers of false-
positive findings that could not be confirmed in subsequent
validation. Mechanisms contributing to this pattern might
include, for example, differences in tumor characteristics
other than stage (whose distribution was roughly similar in
our study between cases recruited in the clinical and the
screening setting, respectively) or influences of the preced-
ing diagnostic process (e.g., CRC patients recruited in the
clinical setting typically have had a colonoscopy at which
the cancer was diagnosed days to weeks before recruitment).
Regardless of the contributing mechanisms, initial discovery
of markers in the clinical setting resulted in substantially
higher initial false-positive rates than initial discovery in
the screening setting. This pattern would be expected to be
even more pronounced in studies taking less care to over-
come other aforementioned potential sources of bias.
Despite the expected higher initial false positivity rate, it
may often be reasonable to start biomarker discovery using
patients recruited in clinical settings [18,19]. The main
reason is that identification of sufficiently large numbers
of cases in true screening settings, if feasible at all, typi-
cally requires recruitment of very large screening cohorts,given the low prevalence of most preclinical cancers. The
effort for setting up such a cohort or using the precious
samples from existing screening cohorts may not be worth-
while when biomarkers turn out to show poor diagnostic
performance even when using clinically detected cases.
Discovery of candidate biomarkers in a clinical setting,
which typically is much less time consuming and costly,
may therefore often be a reasonable first step. Our analyses
underline, however, the importance of subsequent valida-
tion of findings in a true screening setting to limit the num-
ber of false-positive results. Based on a novel analysis, we
quantitatively report the impact of study settings on the
blood biomarker identification for early detection of cancer.
There are specific strengths and limitations that deserve
careful consideration when interpreting our results.
Strengths include that a large number of biomarkers were
simultaneously measured in samples of equal size from
both a clinical setting and a screening setting, which
enabled a fair comparison of biomarker identification in
both settings. We did not restrain our analysis on single
markers only, but also evaluated all two- and three-
marker combinations, which yielded a very broad empirical
basis for our analyses. In addition, the samples from the
screening setting were subgroups of participants recruited
in a very large cohort of screening colonoscopy, which is
an ideal target population for evaluating the diagnostic per-
formance of novel biomarkers for early detection of CRC.
The limitations include the relatively small sample size
of CRC cases in the screening setting although a very large
number of participants were recruited, which reflects the
very low prevalence of CRC in a screening population.
The same number of cases was selected for the clinical
setting and for the controls. Sample sizes of this order are
common in studies evaluating cancer early detection
markers [8,21]. There were slight differences regarding
age and sex distribution between the CRC cases used in
the two settings. As age and sex are known risk factors
of CRC [29], they could also have affected the confirmation
rates calculated in our analysis. Moreover, only protein bio-
markers were evaluated in our study. Further studies using
other technology or evaluating other biomarkers would be
desirable to supplement our findings. Our analyses only
evaluated CRC as disease outcome. We would anticipate,
however, that similar findings would also apply for other
cancers. Although our study demonstrated major difference
in confirmation rates according to study settings, the overall
diagnostic performance of the biomarkers assessed in this
study was lower than would be desirable for a CRC
screening test. However, similar difference in confirmation
rates according to the study setting might also occur for
tests with higher diagnostic performance.
In conclusion, study designs may strongly affect the val-
idity of studies on biomarkers for early detection of cancer.
The interpretation of caseecontrol studies based on patients
from clinical settings requires particular caution, due to the
potential high proportion of false-positive findings.
114 H. Chen et al. / Journal of Clinical Epidemiology 75 (2016) 108e114Validation of biomarkers for early detection of cancer in
screening settings is important to limit the number of
false-positive findings.Acknowledgments
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